C021 Post hoc Analysis: Effects of Reducing Lamotrigine or Carbamazepine Dose in Patients With Uncontrolled Focal Seizures Receiving Cenobamate

April 17 – 22, 2021; Virtual Meeting
Analysis of seizure-free patients suggests dose of ASMs may be able to be reduced while receiving concomitant cenobamate, without compromising long-term efficacy.
Format: Microsoft PowerPoint (.ppt)
File Size: 536 KB
Released: April 26, 2021

Acknowledgements

Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Greenwich Biosciences, Inc.

Related Content

From Clinical Care Options (CCO), new data from AAN 2021 on CBD add-on therapy in treatment-resistant epilepsy

Released: April 26, 2021

Expert commentary from CCO on key clinical information about each FDA-approved agent for treating spinal muscular atrophy (SMA)

Nancy L. Kuntz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 23, 2020 Expired: October 22, 2021

Expert commentary on how to support, counsel, and educate families with a new diagnosis of spinal muscular atrophy (SMA), from Clinical Care Options (CCO)

Vanessa Battista, MS, RN, CPNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 5, 2020 Expired: October 4, 2021

Expert slides from Clinical Care Options on screening, diagnosis, treatment, and interdisciplinary care for spinal muscular atrophy (SMA)

Samiah Al-Zaidy, MD Vanessa Battista, MS, RN, CPNP Nancy L. Kuntz, MD Released: September 3, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue